Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-022735
Filing Date
2022-08-12
Accepted
2022-08-12 17:12:48
Documents
59
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cpix-20220630.htm   iXBRL 10-Q 1085067
2 EX-10.1 pinnaclebank-cpiamend8tolo.htm EX-10.1 147265
3 EX-31.1 a2022q2-exhibit311.htm EX-31.1 12645
4 EX-31.2 a2022q2-exhibit312.htm EX-31.2 12639
5 EX-32.1 a2022q2-exhibit321.htm EX-32.1 6975
11 imagea.jpg GRAPHIC 34109
  Complete submission text file 0001628280-22-022735.txt   4960565

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20220630.xsd EX-101.SCH 32870
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20220630_cal.xml EX-101.CAL 54079
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20220630_def.xml EX-101.DEF 137090
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20220630_lab.xml EX-101.LAB 407046
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20220630_pre.xml EX-101.PRE 269768
53 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20220630_htm.xml XML 673802
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33637 | Film No.: 221161188
SIC: 2834 Pharmaceutical Preparations